BARCELONA, SPAIN and TORONTO, CANADA -- (November 15, 2017) Exact Imaging (www.exactimaging.com), the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, is profiled extensively at the 6th Annual ESUI (EAU Section of Urological Imaging) 2017, which is being held on November 16, 2017 in Barcelona, Spain. The ExactVu technology will be discussed in two clinical talks, in four posters including two presentations and as a key technology in the Hands-On Training MRI/Ultrasound Fusion Workshop.

“As the ExactVu micro-ultrasound system is growing its installed base globally, it is becoming an essential tool for our customers to successfully visualize suspicious regions, to perform targeted biopsies and to thereby improve their detection of significant cancer,” says Randy AuCoin, Exact Imaging’s President and CEO. “We are pleased to have our micro-ultrasound platform profiled in so many separate instances at the ESUI, which represents some of the most prolific thinking in European imaging.  Sharing evidence on the benefits of micro-ultrasound is an important indicator of the growing adoption of this technology into the urological community globally.”

ExactVu micro-ultrasound and the PRI-MUS™ (prostate risk identification using micro-ultrasound) risk identification protocol are featured in the following talks: “High resolution ultrasound and fusion biopsy” by Dr. Lars Budäus (Martini Clinic, Hamburg, Germany) and “Feasibility Study for avoiding or postponing biopsy using improved imaging: Negative predictive value of micro-ultrasound for subjects with low PSAD” by Dr. Ander Astobieta Odriozola (Urología Clínica Bilbao, Urología Clínica, Bilbao, Spain). They are also featured in the four following clinical posters:

• Initial Results Comparing 29 MHz Micro-Ultrasound with Multi-Parametric MRI for Targeted Prostate Biopsy: Relative Sensitivity to Clinically Significant Prostate Cancer, Astobieta A. et al.
  
  
• Feasibility Study for Avoiding or Postponing Biopsy using Improved Imaging: Negative Predictive Value of Micro-Ultrasound for Subjects with Low PSAD, Astobieta A et al.
  
  
• Correlating Micro-Ultrasound Sonographic Features and PRI-MUS™ Ranking of
  Prostate Cancer Lesions with Underlying Histo-pathology, J. Lin et al.
  
  
• Comparison of Conventional TRUS, MRI and Micro-Ultrasound for Visualizing Prostate Cancer in an Active Surveillance Population: A Feasibility Study, G. Eure et al.

The 6th EAU Section of Urological Imaging (ESUI) meeting will be held on November 16, 2017 in Barcelona, Spain at the Palau de Congressos de Catalunya in conjunction with the 9th European Multidisciplinary Meeting on Urological Cancers (EMUC). The ESUI’s theme, “New technologies and limited resources”, will address when and how such new imaging technologies can provide true benefit for patients and how they can be implemented in clinical practice in a cost-effective way.

About Exact Imaging
Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas, aided by the PRI-MUS™ (prostate risk identification using micro-ultrasound) evidence-based micro-ultrasound protocol. For the minority of cases where MRI might assist (i.e., prior negative biopsies), FusionVu™ is the forthcoming micro-US/MRI fusion application operating on the ExactVu micro-ultrasound platform. The ExactVu micro-ultrasound system has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).